The c-Myc-tag role in anti-CD19 scFv labeling and CAR's function alteration: an in silico, in vitro and in vivo study

Lima, Ana Julia Ferreira; Hajdu, Karina Lôbo; Abdo, Luiza de Macedo; Bonamino, Martín Hernán; Lourenzoni, Marcos Roberto.
No convencional en Inglés | ARCA | ID: arc-52184

Documentos relacionados

  1. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.
  2. [Clinical effect of recombinant human interferon α1b adjuvant therapy in infectious mononucleosis: a prospective randomized controlled trial].
  3. Optimized CD19/CD22/CD3 antibody.
  4. Spacer Length Modification Facilitates Discrimination between Normal and Neoplastic Cells and Provides Clinically Relevant CD37 CAR T Cells.
  5. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma.
  6. Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
  7. Axicabtagene Ciloleucel in Large B-Cell Lymphoma. Reply.
  8. Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics.
  9. Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22.
  10. Impaired B cell terminal differentiation in B cell-specific knockout mice of cell death-defying factor anamorsin.